Currently submitted to: JMIR Preprints
Date Submitted: Jun 14, 2020
Open Peer Review Period: Jun 14, 2020 - May 30, 2021
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Serum Ferritin Levels in Alzheimer's Disease: A Meta-Analysis
ABSTRACT
Background:
The role of iron overload in Alzheimer’s Disease (AD) pathology has been investigated in previous years, but mechanisms underlying overload remain unclear. Ferritin is an iron storage and transport protein that has been associated with inflammation and neurodegenerative disease.
Objective:
The objective of this study was to evaluate if serum ferritin levels in AD subjects are significantly higher than serum ferritin levels among a healthy control.
Methods:
A systematic literature search of the PubMed database yielded fifty publications, culminating in two studies that were used in statistical analysis.
Results:
Our results showed that pooled serum ferritin levels were significantly higher in AD patients than in healthy controls [SMD: 1.06, 95 % CI: (0.68, 1.43), z = 5.53, p ≈ 0.00].
Conclusions:
Findings from this study suggest that serum ferritin may be a potent blood biomarker for AD. Research must be conducted to further evaluate the role of serum ferritin as a neurotoxic, neuroprotective, or an indicator molecule in AD pathology. We propose that increased serum ferritin levels in AD may contribute to neuroinflammation and iron overload in neuroglia.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.